Spök Armin, Gaugitsch Helmut, Laffer Sylvia, Pauli Gabrielle, Saito Hirohisa, Sampson Hugh, Sibanda Elopy, Thomas Wayne, van Hage Marianne, Valenta Rudolf
Inter-University Research Centre for Technology, Work, and Culture, Graz, Austria.
Int Arch Allergy Immunol. 2005 Jun;137(2):167-80. doi: 10.1159/000086315. Epub 2005 Jun 8.
The prevalence of allergic diseases has been increasing continuously and, accordingly, there is a great desire to evaluate the allergenic potential of components in our daily environment (e.g., food). Although there is almost no scientific evidence that genetically modified organisms (GMOs) exhibit increased allergenicity compared with the corresponding wild type significant concerns have been raised regarding this matter. In principle, it is possible that the allergenic potential of GMOs may be increased due to the introduction of potential foreign allergens, to potentially upregulated expression of allergenic components caused by the modification of the wild type organism or to different means of exposure. According to the current practice, the proteins to be introduced into a GMO are evaluated for their physiochemical properties, sequence homology with known allergens and occasionally regarding their allergenic activity. We discuss why these current rules and procedures cannot predict or exclude the allergenicity of a given GMO with certainty. As an alternative we suggest to improve the current evaluation by an experimental comparison of the wild-type organism with the whole GMO regarding their potential to elicit reactions in allergic individuals and to induce de novo sensitizations. We also recommend that the suggested assessment procedures be equally applied to GMOs as well as to natural cultivars in order to establish effective measures for allergy prevention.
过敏性疾病的患病率一直在持续上升,因此,人们非常希望评估我们日常环境中各种成分(如食物)的致敏潜力。尽管几乎没有科学证据表明转基因生物(GMO)与相应的野生型相比具有更高的致敏性,但人们对此事仍提出了重大担忧。原则上,转基因生物的致敏潜力可能会因引入潜在的外源过敏原、野生型生物体修饰导致的致敏成分表达可能上调或不同的接触方式而增加。根据目前的做法,会对拟引入转基因生物的蛋白质进行物理化学性质评估、与已知过敏原的序列同源性评估,偶尔还会评估其致敏活性。我们讨论了为什么这些现行规则和程序无法确定地预测或排除特定转基因生物的致敏性。作为一种替代方法,我们建议通过对野生型生物体和整个转基因生物在引发过敏个体反应和诱导新发致敏方面的潜力进行实验比较,来改进当前的评估。我们还建议将所建议的评估程序同样应用于转基因生物以及天然品种,以便建立有效的过敏预防措施。